Home Cart Sign in  
Chemical Structure| 1323403-33-3 Chemical Structure| 1323403-33-3

Structure of Iberdomide
CAS No.: 1323403-33-3

Chemical Structure| 1323403-33-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CC-220 is a modulator of cereblon that is potential to treat systemic lupus erythematosis and multiple myeloma.

Synonyms: CC-220

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Iberdomide

CAS No. :1323403-33-3
Formula : C25H27N3O5
M.W : 449.50
SMILES Code : O=C([C@@H](N(CC1=C2C=CC=C1OCC3=CC=C(CN4CCOCC4)C=C3)C2=O)CC5)NC5=O
Synonyms :
CC-220
MDL No. :MFCD31382133
InChI Key :IXZOHGPZAQLIBH-NRFANRHFSA-N
Pubchem ID :67335295

Safety of Iberdomide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • CRBN

    cereblon, IC50:60 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
KMS12BM cells 0.1 μM Evaluated Aiolos degradation kinetics, showing iberdomide rapidly degraded Aiolos PMC7214241
KMS12BM/PR cells 0.1 μM Evaluated Aiolos degradation kinetics, showing only iberdomide effectively induced Aiolos degradation PMC7214241
MM1.S cells 0.0001–1 μM Evaluated antiproliferative and pro-apoptotic activity in combination with bortezomib, showing synergistic effects PMC7214241
H929/LR cells 0.1 μM Evaluated antiproliferative activity, showing iberdomide had higher activity than pomalidomide and lenalidomide PMC7214241
H929 cells 0.1 μM Evaluate the effect of MYCi975 on H929 cells, showing MYCi975 enhanced T cell-mediated killing of H929 cells PMC7214241
Primary CD4+ T cells 10 μM 48 hours Evaluate the effect of Iberdomide on latency reversal, showing significant reversal of latency. PMC9177988
ED40515 cells 1.5 µM 3 days Evaluate the growth inhibitory effect of LEN on ATL cells, results showed that LEN-resistant ED40515 cells did not exhibit significant growth inhibition after LEN treatment PMC10853999
OATL4 cells 1.5 µM 3 days Evaluate the growth inhibitory effect of LEN on ATL cells, results showed that LEN-resistant OATL4 cells did not exhibit significant growth inhibition after LEN treatment PMC10853999
TL-Om1 cells 1.5 µM 3 days Evaluate the growth inhibitory effect of LEN on ATL cells, results showed that LEN-sensitive TL-Om1 cells exhibited significant growth inhibition after LEN treatment PMC10853999
HuT102 cells 1.5 µM 3 days Evaluate the growth inhibitory effect of LEN on ATL cells, results showed that LEN-sensitive HuT102 and TL-Om1 cells exhibited significant growth inhibition after LEN treatment PMC10853999
B cells from SLE patients 10 nM 5 days To evaluate the effects of Iberdomide on B cell differentiation into plasmablasts. Results showed that Iberdomide significantly inhibited the differentiation of B cells into plasmablasts and plasma cells and reduced antibody production. PMC7970264
CD19+ B cells from SLE patients 1, 10, 100 nM 5 days To evaluate the effects of Iberdomide on the activation and differentiation of B cells from SLE patients. Results showed that Iberdomide significantly inhibited TLR7 and IFNα-mediated immunoglobulin production and reduced the number of CD27+CD38+ plasmablasts and CD138+ plasma cells. PMC7970264
Human T cells 10 nM 6 hours Acute treatment reveals direct effects of IKZF1 degradation, increasing chromatin accessibility PMC11604474
Human T cells 10 nM 14 days Acute treatment reveals direct effects of IKZF1 degradation, increasing chromatin accessibility PMC11604474
H929 cells 10–20 nM 4 months Evaluate the effect of MYCi975 on H929 cells, showing MYCi975 enhanced T cell-mediated killing of H929 cells PMC11010819
CD27-IgD-DN B cells 10 nM 5 days CC-220 inhibited BAFF- and CD40L-induced plasmablast differentiation and IgG and IgM secretion PMC5602157
CD27+ memory B cells 1, 10, and 100 nM 24 hours CC-220 significantly reduced Aiolos and Ikaros protein levels and inhibited both BAFF, IL-2, and IL-21–induced and CD40L, IL-2, and IL-21–induced proliferation, plasmablast differentiation, and Ab secretion PMC5602157

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB17-SCID mice HuT102 cell xenograft model Oral 10 mg/kg, 50 mg/kg, 100 mg/kg Once daily for 28 days Evaluate the anti-tumor effect of LEN on ATL cell xenograft mouse model, results showed that the mean tumor volumes in all three LEN-treated groups were significantly lower than the control group PMC10853999

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05354557 Multiple Myeloma PHASE2 RECRUITING 2025-04-26 Memorial Sloan Kettering Baski... More >>ng Ridge (Consent and Followup), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (Consent and Follow-Up only), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (Consent and Follow up), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Suffolk-Commack (Consent and Follow up), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (Consent and Follow Up), Harrison, New York, 10604, United States|Weill Cornell Medical College (Data Collection Only), New York, New York, 10021, United States|Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (Consent and Followup), Rockville Centre, New York, 11553, United States Less <<
NCT05177536 Multiple Myeloma PHASE2 RECRUITING 2025-01-31 University of Nebraska Medical... More >> Center, Omaha, Nebraska, 68198, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States Less <<
NCT04564703 Multiple Myeloma PHASE2 ACTIVE_NOT_RECRUITING 2025-12-27 CHU H?tel-Dieu, 1, place Alexi... More >>s Ricordeau, 44093 NANTES Cedex 1, FRANCE, Nantes, France|Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens, Greece|Ospedale Generale Regionale-Divisione di Ematologia e Centro Trapianto Midollo Osseo, Bolzano, Italy|Vrije Universiteit Medical Center (VUMC), Amsterdam, Netherlands Less <<
NCT03135509 Healthy Volunteers PHASE1 COMPLETED 2017-06-28 Quintiles Phase One Services, ... More >>LLC, Overland Park, Kansas, 66211, United States Less <<
NCT03824678 Hepatic Impairment|Healthy Vol... More >>unteers Less << PHASE1 COMPLETED 2019-06-18 Clinical Pharmacology of Miami... More >>, LLC, Miami, Florida, 33014-3616, United States|Orlando Clinical Research Center OCRC, Orlando, Florida, 32809, United States|The Texas Liver Institute, San Antonio, Texas, 78215, United States Less <<
NCT05899738 Healthy Volunteers PHASE1 COMPLETED 2023-07-06 Local Institution - 0001, Dayt... More >>ona Beach, Florida, 32117, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.22mL

0.44mL

0.22mL

11.12mL

2.22mL

1.11mL

22.25mL

4.45mL

2.22mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories